Medtronic Study Site Warned By FDA for Shocking Consent and Reporting Irregularities in Study Of CoreValve Device
April 16th, 2013 // 1:21 pm @ jmpickett
More Exclusive FDA cGMP Compliance News
The FDA sent a warning letter to Providence Sacred Heart Medical Center in Spokane, Washington regarding serious irregularities in its study of the Medtronic CoreValve device. The device is intended for patients with severe aortic stenosis, a condition that may lead to heart failure and sudden cardiac death. Medtronic promoted the clinical trial of its device and has multiple centers utilizing it at this time in conjunction with the trial. The trial makes use of a non-FDA approved, investigational device for transcatheter aortic valve implantation (TAVI). Â Flagrant violations of trial protocols were recently identified by the FDA which led to the FDA sending a warning letter to the site and manufacturer and its principal investigators.
- April 25 – How to Survive PREDICT – FDA’s New Import Screening Program
- April 29 – Audit Your Lab Like an Expert FDA Auditor: A Roadmap to Lab Compliance
The reported violations include:
1. A researcher failed to obtain informed consent from subjects who underwent screening tests that were research-specific, such as CT angiograms. Â These tests have various risks to patients, and the failure to obtain the necessary consent is a substantial concern.
2. Some patients were already in the clinical trial before signing consents, and one consent was signed more than two months after beginning the clinical trial.
3. Timely notification to the manufacturer and the Institutional Review Board was withheld when some significant clinical events occurred that deviated from the original investigational plan. Â A patient underwent several surgeries, two of them emergently, and the events were not reported for over a month, far beyond the five day period the rules require. Â A coronary bypass was performed on another patient, and it was not reported at all. Â Of greatest concern, two patients died and their deaths were reported late. Â Timely reporting is a cornerstone to safe clinical trials and allows for adjustments and discontinuance of studies when appropriate.
4. The FDA also found flaws in the maintenance of general medical records pertaining to the subjects, including failing to record baseline vital signs, lab values and postop ECGs.
The FDA is requiring correction and compliance with the applicable rules, and Medtronic has indicated that the violations are limited to this one site.
Upcoming Expertbriefings.com Webinars
- May 2 – Avoid the CDRH eCopy Chaos – How to Prepare a Compliant eCopy Submission
- April 16 – The Quality Manager Gets Fired, the $100,000 Compliance SNAFU, and 21 Tips and Tricks for Your Next Audit
- April 18 – Why You May Want to Move Your Pharma Company to Kansas – 483 and Warning Letter Trends
- April 25 – How to Survive PREDICT – FDA’s New Import Screening Program
- April 29 – Audit Your Lab Like an Expert FDA Auditor: A Roadmap to Lab Compliance
- May 1 – Avoiding Warning Letter Disasters With a Strong Contractor Quality Agreement
- May 7 – FDA Recall Chief Update – How to Design a Bulletproof Product Recall Strategy
